Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B. Mennecier

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Journal of Thoracic Oncology

Respiratory Medicine

English

EGFR-TKI and Lung Adenocarcinoma With CNS Relapse: Interest of Molecular Follow-Up

European Respiratory Journal

Respiratory Medicine

English

Related publications

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English